SCHEMBL3337055

SCHEMBL3337055

CC(C)Oc1nc(N)nc2ccc(-c3ccoc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ADORA2A P29274 2/20 0.45
CLK4 Q9HAZ1 12/20 0.41
ALDH1A1 P00352 11/20 0.41
CYP1A2 P05177 11/20 0.41
CYP3A4 P08684 10/20 0.41
CYP2D6 P10635 9/20 0.41
LMNA P02545 7/20 0.41
CYP2C19 P33261 6/20 0.41
MAPK1 P28482 4/20 0.41
USP2 O75604 8/20 0.39
MEN1 O00255 6/20 0.39
KMT2A Q03164 6/20 0.39
TSHR P16473 3/20 0.39
HSD17B10 Q99714 5/20 0.38
CASP1 P29466 1/20 0.38
HIF1A Q16665 4/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3333937 0.83 DHFR (0.48) ATMDHFRCDK2
SCHEMBL3336033 0.82 HRH1 (0.46) HRH1HRH4HRH3ADORA2ACLK4
SCHEMBL3333131 0.82 HSP90AB1 (0.47) HRH4ADORA2AMEN1KMT2AATM
SCHEMBL3332604 0.81 AAK1 (0.44) ATMDHFR
SCHEMBL3338126 0.81 MAP4K4 (0.43) ADORA2ACYP1A2CYP2C19CYP2C9ATM
SCHEMBL3336166 0.81 ATM (0.39) TSHRATMDHFRCDK2
SCHEMBL3337214 0.81 ATM (0.53) ATMDHFRCDK2
SCHEMBL3334043 0.80 MAP4K4 (0.45) ADORA2AATMDHFRCDK2
SCHEMBL3335845 0.80 ALOX5AP (0.40) ATMDHFRCDK2
SCHEMBL3338593 0.79 ADORA2A (0.49) HRH1HRH4HRH3ADORA2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 HRH1 124/4885HRH4 18/4885HRH3 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.